Exosome-Based Treatment Targeting KRAS G12D-Mutated Pancreatic Cancer to Enter Human Studies Next Month – Precision Oncology News


NEW YORK Researchers have been hunting for ways to target alterations in KRAS ever since the mutated gene was first discovered in cancer in the early 1980s. Now, as drugmakers race to bring the first drugs targeting mutated KRAS protein to cancer patients, one scientist at MD Anderson Cancer Center is trying a different approach to get at this elusive target: exosomes.

Premium Access gives you: Full site access Interest-based email alerts Access to archives Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?Login Now.

*Before your trial expires, well put together a custom quote with your long-term premium options.

See the article here:
Exosome-Based Treatment Targeting KRAS G12D-Mutated Pancreatic Cancer to Enter Human Studies Next Month - Precision Oncology News

Related Posts